VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY

血管病、细胞凋亡和自身免疫

基本信息

  • 批准号:
    6655100
  • 负责人:
  • 金额:
    $ 26.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-09-27 至 2005-08-31
  • 项目状态:
    已结题

项目摘要

This proposal is focused upon the molecular mechanism by which vasculopathy leads to fibrotic and autoimmune manifestations of systemic sclerosis. Autoantibodies generated by patients with systemic sclerosis are uniquely targeted to nucleolar proteins such as DNA topoisomerase I (topo-I). It has been demonstrated that topo-I is a substrate for protease(s) specific to the apoptotic process, resulting in novel cleavage fragments that may reveal cryptic epitopes to which the host has not previously been tolerized. It has also been recently demonstrated that several of the autoantigens targeted in diffuse scleroderma are uniquely susceptible to cleavage by metal-catalyzed oxidation reactions similar to what may occur during ischemia-reperfusion in the presence of appropriate metals. This process may also reveal immunocryptic epitopes and provides a molecular explanation for why certain proteins are uniquely targeted by the immune response in systemic sclerosis. However, it is well known that a cryptic epitope alone is not sufficient to generate autoreactivity, which also requires the participation of a molecular adjuvant, and uptake of the potential autoantigen by an antigen presenting cell (APC) with costimulatory capacity. The central hypothesis of this proposal is that chronic ischemia-reperfusion injury in patients with systemic sclerosis not only generates immunocryptic epitopes within nucleolar autoantigens of cutaneous origin, but it also generates complement ligands that provide the molecular adjuvant required to break immune tolerance. The specific aims of this proposal are to: 1) Determine the capacity of apoptotic blebs bearing complement ligands to modulate the cytokine expression and costimulatory capacity of antigen presenting cells, 2) characterize the immune responses to self antigen- containing apoptotic blebs, and 3) examine the role of complement ligand C3d during induction of autoreactive T and B cell responses to topo I in vitro. Although systemic sclerosis is the focus of this proposal, the data generated by these studies should provide insight into our understanding of vasculopathic and autoimmune processes in general.
这一建议是集中在分子机制的血管病变导致纤维化和自身免疫性表现的系统性硬化症。系统性硬化症患者产生的自身抗体是唯一针对核蛋白的,如DNA拓扑异构酶I (topo-I)。已经证明,topo- 1是凋亡过程特异性蛋白酶的底物,导致新的裂解片段可能揭示宿主以前不耐受的隐表位。最近也有研究表明,弥漫性硬皮病中靶向的几种自身抗原特别容易被金属催化的氧化反应裂解,类似于在缺血-再灌注中存在适当金属时可能发生的反应。这一过程也可能揭示免疫隐表位,并为为什么某些蛋白质是系统性硬化症免疫反应的唯一目标提供了分子解释。然而,众所周知,单独的隐表位不足以产生自身反应性,这还需要分子佐剂的参与,并由具有共刺激能力的抗原提呈细胞(APC)摄取潜在的自身抗原。该建议的中心假设是,系统性硬化症患者的慢性缺血再灌注损伤不仅在皮肤来源的核仁自身抗原内产生免疫隐性表位,而且还产生补体配体,提供打破免疫耐受所需的分子佐剂。本研究的具体目的是:1)确定携带补体的凋亡泡调节细胞因子表达和抗原提呈细胞共刺激能力的能力;2)表征对含有自身抗原的凋亡泡的免疫反应;3)检测补体配体C3d在体外诱导自身反应性T细胞和B细胞对topo I的反应中的作用。虽然系统性硬化症是本研究的重点,但这些研究产生的数据应该为我们对血管病变和自身免疫过程的理解提供深入的见解。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Apoptosis, complement and systemic lupus erythematosus: a mechanistic view.
细胞凋亡、补体和系统性红斑狼疮:机制观点。
  • DOI:
    10.1159/000075687
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Liu,Chau-Ching;Navratil,JeannineS;Sabatine,JaniceM;Ahearn,JosephM
  • 通讯作者:
    Ahearn,JosephM
Apoptosis and immune responses to self.
细胞凋亡和对自身的免疫反应。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph M Ahearn其他文献

Joseph M Ahearn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph M Ahearn', 18)}}的其他基金

Complement, Cardiovascular Disease, and SLE
补体、心血管疾病和系统性红斑狼疮
  • 批准号:
    6805641
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    6772602
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    7105057
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    6924619
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Complement, Cardiovascular Disease, and SLE
补体、心血管疾病和系统性红斑狼疮
  • 批准号:
    6898927
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Complement, Cardiovascular Disease, and SLE
补体、心血管疾病和系统性红斑狼疮
  • 批准号:
    6733758
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Complement, Cardiovascular Disease, and SLE
补体、心血管疾病和系统性红斑狼疮
  • 批准号:
    7077805
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in Systemic Lupus Erythematosus
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    7253944
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    6677400
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
DAMAGE AND PATHOLOGIC FRACTURE IN VERTEBRAL BODIES
椎体损伤和病理性骨折
  • 批准号:
    6232932
  • 财政年份:
    2001
  • 资助金额:
    $ 26.25万
  • 项目类别:

相似海外基金

Understanding and exploiting DNA topoisomerases in cancer biology
了解和利用癌症生物学中的 DNA 拓扑异构酶
  • 批准号:
    10296437
  • 财政年份:
    2021
  • 资助金额:
    $ 26.25万
  • 项目类别:
Understanding and exploiting DNA topoisomerases in cancer biology
了解和利用癌症生物学中的 DNA 拓扑异构酶
  • 批准号:
    10473793
  • 财政年份:
    2021
  • 资助金额:
    $ 26.25万
  • 项目类别:
Structural and mechanistic analysis of type II DNA topoisomerases
II 型 DNA 拓扑异构酶的结构和机制分析
  • 批准号:
    2059935
  • 财政年份:
    2018
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Studentship
Conference: 2016 Gordon Research Seminar on DNA Topoisomerases to be held at Sunday River in Newry, ME on August 6-7, 2016
会议:2016 年戈登 DNA 拓扑异构酶研究研讨会将于 2016 年 8 月 6 日至 7 日在缅因州纽里的 Sunday River 举行
  • 批准号:
    1643077
  • 财政年份:
    2016
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Standard Grant
2014 DNA Topoisomerases in Biology and Medicine Gordon Research Conference
2014 DNA 拓扑异构酶在生物学和医学戈登研究会议
  • 批准号:
    8714782
  • 财政年份:
    2014
  • 资助金额:
    $ 26.25万
  • 项目类别:
Biochemical Analyses of Type II DNA Topoisomerases
II 型 DNA 拓扑异构酶的生化分析
  • 批准号:
    7909236
  • 财政年份:
    2009
  • 资助金额:
    $ 26.25万
  • 项目类别:
DNA TOPOISOMERASES & LATE CELL CYCLE CHECKPOINTS
DNA拓扑异构酶
  • 批准号:
    6976458
  • 财政年份:
    2004
  • 资助金额:
    $ 26.25万
  • 项目类别:
DNA TOPOISOMERASES & LATE CELL CYCLE CHECKPOINTS
DNA拓扑异构酶
  • 批准号:
    6470650
  • 财政年份:
    2001
  • 资助金额:
    $ 26.25万
  • 项目类别:
DNA Topoisomerases and DNA Topology in E. coli
大肠杆菌中的 DNA 拓扑异构酶和 DNA 拓扑
  • 批准号:
    0090880
  • 财政年份:
    2001
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Continuing Grant
DNA TOPOISOMERASES & LATE CELL CYCLE CHECKPOINTS
DNA拓扑异构酶
  • 批准号:
    6327943
  • 财政年份:
    2000
  • 资助金额:
    $ 26.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了